3 April 2024 - The MSAC Secretariat has published a list of applications scheduled to be considered by the MSAC on 1-2 August 2024.

The agenda currently has 9 items. Applications of note include:

• 1507.1 – Germline BRCA mutation testing in patients with locally advanced or metastatic HER2 negative breast cancer to determine eligibility for PBS listed olaparib
• 1728 – Etranacogene dezaparvovec for the treatment of patients with haemophilia B
• 1732.1 – Imlifidase as a desensitisation treatment to enable kidney transplant in highly sensitised adult transplant candidates
• 1738 – Two testing options to detect early stage Alzheimer's disease, to determine eligibility for PBS listed lecanemab
• 1744 – Lutetium Lu 177 DOTA octreotate treatment for advanced neuroendocrine tumours and other high somatostatin receptor expressing tumours
• 1750 - Testing of tumour tissue to detect IDH1 mutations in patients with cholangiocarcinoma to determine eligibility for PBS listed ivosidenib
• 1771 – Axicabtagene ciloleucel for the treatment of patients with relapsed or refractory follicular lymphoma

Read MSAC agenda